Studies folate receptor alpha testing in women with ovarian cancer
Checks folate receptor alpha in stored tumor samples from adult women with ovarian cancer.
Plain-language title generated from the registry record
Registry title: Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with high grade serous ovarian cancer who have stored tumor tissue from a surgery or biopsy. The tissue will be tested for folate receptor alpha (FRa). No drug is given.
- Age
- 18 years and older
- Sex
- Women only
- Disease stage
- High grade serous ovarian cancer (HGSOC), with tumor tissue available from surgery or biopsy.
- Earlier treatment
- Tissue taken after treatment with Mirvetuximab soravtansine or any other FRa targeted therapy cannot be used.
- Biomarker or test result
- Folate receptor alpha (FRa) is tested on the stored tissue. No result is needed to join.
Main reasons for not taking part
- Tissue sample taken more than 5 years ago
- Fewer than 100 viable tumor cells in the sample
- Tissue taken after Mirvetuximab soravtansine or other FRa targeted therapy
- Tissue from fine needle aspiration, liquid samples or ascites
Read by machine on 9 November 2026.
Where in Canada
- Toronto General Hospital-University Health Network /ID# 282521Toronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AbbVie
- Trial code
- NCT07539844
- Record updated
- 14 September 2026
- Original description
Epithelial ovarian cancer (OC), including fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm with a 5-year relative survival of approximately 50%. This study will evaluate the concordance in folate receptor alpha (FRa) immunohistochemistry (IHC) in adult female participants with ovarian cancer.Read full original descriptionShow less
A Concordance Study of Folate Receptor Alpha (FRa) Testing in InterCon Countries
Epithelial ovarian cancer (OC), including fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm with a 5-year relative survival of approximately 50%. This study will evaluate the concordance in folate receptor alpha (FRa) immunohistochemistry (IHC) in adult female participants with ovarian cancer.
Archived tissue biopsies will be tested for FRa and data from approximately 1,000 participants will be collected. This is a retrospective study and testing will be performed prospectively on archived samples.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 1 Year.
There is no additional burden for participants in this trial.
Inclusion: Surgical or biopsy samples (Formalin Fixed Paraffin Embedded [FFPE]) with tumoral High Grade Serous Ovarian Cancer (HGSOC) material allowing the sectioning of serial slides for all the analyses; Archival specimens should not be older than 5 years in order to control quality of the samples; Specimens containing a minimum of 100 viable tumor cells.
Exclusion: Surgical or biopsy samples (FFPE) with insufficient quantity or quality (sampled more than 5 years ago and/or with less 100 viable tumor cells per section); Tissue obtained following treatment with Mirvetuximab soravtansine or any other FRa targeted therapy; Tissue obtained through fine needle aspirations or liquid specimens, or ascites.